IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
This study is ongoing, but not recruiting participants.
Sponsor:
Bio-Path Holdings, Inc.
Information provided by (Responsible Party):
Bio-Path Holdings, Inc.
ClinicalTrials.gov Identifier:
NCT01159028
First received: July 7, 2010
Last updated: July 25, 2017
Last verified: July 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | September 30, 2017 |
| Estimated Primary Completion Date: | September 30, 2017 (Final data collection date for primary outcome measure) |